GOLIMUMAB, A NEW, HUMAN, TNF-ALPHA ANTIBODY ADMINISTERED SUBCUTANEOUSLY EVERY 4 WEEKS, IN ANKYLOSING SPONDYLITIS: 104-WEEK EFFICACY AND SAFETY RESULTS OF THE RANDOMIZED, PLACEBOCONTROLLED GO-RAISE STUDY
Author(s):
Braun, J.; Heijde, D. van der; Deodhar, A.; Diekman, L.; Sieper, J.; Kim, S.I.; Beutler, A.; Mack, M.; Xu, S.; Zrubek, J.; Hsu, B.; Inman, R.; GO-RAISE Investigators
